BMO lifts HQY target to $125 as shorts quietly rebuild

HealthEquity climbed 7.1% this week to $96.60, with attention from retail investors spiking to unusual levels, yet the stock's own short sellers have been quietly adding to positions over the past month.

The most concrete development came on Tuesday, when BMO Capital's Sean Dodge raised his price target from $105 to $125 while maintaining an Outperform rating. That target now sits 29.4% above the current price. The broader analyst community has been consistently bullish. Deutsche Bank carries a $142 Buy target, Barclays holds Overweight at $115, and RBC and BTIG both rate the stock Outperform or Buy. The mean target across the analyst group is $119.33. Valuation multiples have drifted up alongside the recent price strength: EV/EBITDA has moved from roughly 12.24 to 12.56 over the past week, and the P/E has expanded from near 16.9 to 18.1 over the same stretch. Factor scores are mixed. EPS momentum ranks in the 57th percentile on a 30-day basis, roughly middle of the pack, while the short score rank (21st percentile) and days-to-cover rank (13th percentile) signal that from a purely mechanical short-pressure standpoint, HQY is relatively clean. The bull case rests on continued HSA market share gains, deepening digital monetisation, and AI-driven cost efficiencies. The bear case flags meaningful sensitivity to interest rates, the risk of unemployment rising above 5%, and a valuation at roughly 12.9x 2026 EBITDA that already prices in solid execution.

The positioning story is the one tension worth examining closely. Short interest has risen 23% over the past month, reaching 7.0% of the free float, close to 6 million shares short. On a weekly basis, however, positions edged back down 1.5%. That monthly build happened even as the stock drifted sideways before this week's jump, suggesting bears were adding on perceived weakness rather than chasing momentum. Borrowing costs are low and have been falling: the cost to borrow eased to 0.42%, down 24% over the past month. Availability is extremely loose at 704%, meaning there are roughly seven shares available to lend for every share already short. The lending market places no squeeze pressure here at all. Options positioning is neutral. The put/call ratio at 0.80 is marginally below its 20-day average of 0.81, with a z-score of essentially zero. That is a striking contrast to late September, when the PCR ran above 1.0 for several consecutive sessions. Hedging demand has retreated as the stock has recovered. The overall read is that shorts are rebuilding cautiously on the margin without any conviction squeeze risk in the borrow market.

The retail attention signal is notable this week. The ORTEX Wikipedia/stock-page attention measure, which tracks retail-oriented page views and browsing against the prior 90-day baseline, hit a z-score of 4.95 as of Sunday. That is an unusually large spike. No alt-data dataset for HealthEquity has been measured to lead its reported figures, so this cannot be linked to any fundamental signal. It reflects elevated retail interest in the stock, perhaps following the BMO move or the week's price gain, rather than anything that can be connected to HSA membership trends or revenue.

On ownership, BlackRock remains the largest reported holder at 13.6% of shares, having added roughly 746,000 shares in the quarter to September. Wasatch Advisors holds 8.5% but filed a 13G/A in October showing a reduction from 9.5% previously. Fidelity's FMR filed a 13G/A in November showing 4.1%, having dipped below the 5% reporting threshold. No 13D activist is on the register. Insider activity this month was minimal: the EVP for Product and Strategy bought 108 shares for roughly $9,800 on October 15, a token purchase. The October 6 tax-withholding transactions across the CEO, CFO, General Counsel and other officers, all coded as F-type filings, are compensation mechanics rather than discretionary selling. The 90-day net insider position is modestly negative at around -7,600 shares.

Earnings are next on December 1. The prior print in September produced a one-day gain of 2.1% before giving back more than 3% over the following week. The August print before that was sharper: the stock fell 7.7% on the day and extended losses to roughly 5.4% over five sessions. With the stock having recovered strongly this week and shorts rebuilding on a monthly basis, the setup heading into December will likely hinge on whether the interest-rate sensitivity embedded in the bear case has begun to show up in custodial cash yields.